Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 2.4 mg in overweight or obesity
NCT04251156Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2020
- Primary completion
- Aug 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Semaglutide with Placebo (2 arms). Primary endpoints: Change From Baseline in Body Weight (Percentage) at 44 weeks and Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to 5% at 44 weeks. Started Dec 2020; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04251156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04251156.